Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Ipilimumab Retreatment in Advanced RCC
NCT04088500Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2020
- Primary completion
- Nov 2021
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of ipilimumab in renal cell carcinoma (RCC), sponsored by Bristol Myers Squibb. Started Sep 2020; status: terminated.
02
Drugs
ipilimumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT04088500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04088500.